Latin America Pharmaceutical Drug Delivery Market worth $102.1 billion by 2031
The report "Latin America Pharmaceutical Drug Delivery Market by Route of Administration [Injectable (Prefilled Syringe, Self Injection Devices), Oral (Tablet, Capsule, Liquid), Topical, Buccal, Nasal, Rectal], Application (Cancer, Diabetes, CVD) - Forecast to 2031", is projected to grow from USD 75.3 billion in 2026 and to reach USD 102.1 billion by 2031, at a Compound Annual Growth Rate (CAGR) of 6.3% during the forecast period.
Browse 250 market data Tables and 100 Figures spread through 250 Pages and in-depth TOC on "Latin America Pharmaceutical Drug Delivery Market by Route of Administration [Injectable (Prefilled Syringe, Self Injection Devices), Oral (Tablet, Capsule, Liquid), Topical, Buccal, Nasal, Rectal], Application (Cancer, Diabetes, CVD) - Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/latin-america-pharmaceutical-drug-delivery-market-218162993.html
The Latin America pharmaceutical drug delivery market is experiencing growth due to the rising prevalence of chronic diseases in major countries such as Brazil, Mexico, Argentina, Colombia, and Chile. Additionally, there is an increasing adoption of biologics and complex therapies. This trend is prompting both the public and private healthcare sectors to seek drug-delivery solutions that improve patient compliance while ensuring precision and convenience.
Drug delivery methods such as autoinjectors, inhalers, wearable injectors, lipid nanoparticles, and controlled-release formulations have gained popularity in the region. This shift reflects a move towards advanced therapeutic approaches, including mRNA-based treatments, cell & gene therapies, and high-viscosity biologics. These delivery systems not only help maintain drug stability but also facilitate accurate dosing, thereby improving patient adherence. This is particularly important given the growing trend of home-based and self-administration treatments in Latin America.
However, the market still faces challenges, including exorbitant costs and the technical difficulties associated with developing drug-device combinations. Specialized manufacturing capabilities, strict regulatory requirements, and lengthy development cycles remain significant obstacles. Furthermore, regulatory bodies in Latin America, such as ANVISA in Brazil, COFEPRIS in Mexico, ANMAT in Argentina, and INVIMA in Colombia, are progressively raising their expectations regarding safety, usability, and drug-device compatibility. This, in turn, increases the burden on manufacturers in the region.
“Based on route of administration, the injectable drug delivery segment is expected to grow at the highest CAGR globally during the forecast period."
Among the various segments of the Latin America pharmaceutical drug delivery market, the injectable segment is expected to experience the strongest growth. This growth is primarily driven by the rapid expansion of biologics, biosimilars, monoclonal antibodies, and mRNA-based treatments. These advanced therapies often rely on parenteral routes due to their poor oral bioavailability, structural sensitivity, and the need for precise systemic delivery. Additionally, advancements in drug formulation and device engineering are contributing to this growth. Innovations such as autoinjectors, prefilled syringes, needle safety systems, depot injections, and wearable body injectors are enhancing dosing accuracy, reducing contamination risks, improving patient comfort, and facilitating self-administration. These developments significantly impact the use of injectable delivery platforms in both developed and emerging healthcare markets across Latin America.
“The autoimmune diseases segment is projected to experience the highest CAGR in the Latin America pharmaceutical drug delivery market during the forecast period.”
The autoimmune diseases market segment is one of the fastest-growing sectors within the Latin America pharmaceutical drug delivery market. Several key factors are driving this growth, including the rising prevalence of diseases such as rheumatoid arthritis, psoriasis, inflammatory bowel diseases, multiple sclerosis, and lupus in major countries such as Brazil, Mexico, Argentina, and Colombia. Additionally, there is a rising trend toward biologics, targeted immunotherapies, biosimilars, and personalized treatment options. In this region, the primary focus of autoimmune therapy is on innovative drug-delivery systems, including injectable drugs, monoclonal antibodies, antibody-drug conjugates, and subcutaneous biologic agents. These therapies require highly accurate, consistent, and patient-friendly drug delivery systems to optimize therapeutic effects while minimizing systemic side effects. Pharmaceutical companies are increasingly developing innovative drug delivery systems to meet the growing treatment needs for autoimmune diseases in Latin America. As a result, there has been a shift towards the adoption of injectable, implantable, and localized delivery systems, such as long-acting depots, nanoparticle formulations, autoinjectors, on-body injectors, and prefilled syringes for chronic and self-managed conditions. These systems enable targeted and controlled dosing, supporting long-term disease management while improving patient adherence and reducing the need for clinic visits.
“By facility of use, the hospitals segment is the largest contributor to the Latin America pharmaceutical drug delivery market.”
The hospitals segment holds a dominant share of the Latin America pharmaceutical drug delivery market, primarily due to the high prevalence of chronic and acute diseases in the region. These conditions often require complex treatments, typically administered in controlled clinical environments. Hospitals serve as the main centers for oncology, infectious disease management, critical care, and biologics not only in Brazil but also in Mexico, Argentina, and Colombia. The presence of trained medical personnel, state-of-the-art diagnostic and monitoring facilities, and the ability to handle high-viscosity biologics, monoclonal antibodies, radiopharmaceuticals, and other specialty therapies contribute to this trend. Moreover, hospital settings are becoming increasingly important as the use of long-acting injectables, controlled-release formulations, and implantable delivery systems rises, all of which necessitate professional supervision for accurate dosing and safety. Additionally, centralized procurement systems, government-backed reimbursement schemes, and a continuous influx of investments in hospital upgrades throughout Latin America sustain the dominance of this segment.
Key Market Players
Some of the prominent players in the Latin America pharmaceutical drug delivery market include Pfizer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Sanofi (France), AstraZeneca (UK), GSK Plc (UK), Eurofarma (Brazil), Bayer AG (Germany), EMS (Brazil), BD (US), Teva Pharmaceutical Industries Ltd. (Israel), and Hypera Pharma (Brazil). These companies are key contributors to the industry in this region.
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Latin America Pharma
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
